ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026
Antibody-mediated rejection in ABO-incompatible kidney transplantation.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in antibody-mediated rejection of renal allografts.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background and hypothesisIn ABO-incompatible (ABOi) kidney transplantation, C4d deposition is associated with accommodation rather than rejection. Isoagglutinins targeting blood group antigens A/B are also classified as donor-specific antibodies (DSA). Therefore, the diagnosis of antibody-mediated rejection (AMR) relies primarily on microvascular inflammation (MVI).
methodsWe analyzed 66 ABOi and 251 ABO-compatible (ABOc) kidney transplant recipients (KTRs) concerning anti-human leukocyte antigen (HLA) DSA development. Forty-six protocol biopsies from ABOi KTRs were classified according to Banff 2022. In addition, 25 ABOi protocol biopsies were assessed by the Molecular Microscope Diagnostics System (MMDx) and compared with ABOc biopsies: (i) 35 DSA-negative, C4d-negative cases with MVI <2, (ii) 16 C4d-positive cases with MVI <2, (iii) 35 DSA-positive, C4d-negative cases with MVI = 1 (probable AMR) and (iv) 87 C4d-negative/positive cases with MVI ≥2.
resultsABOi KTRs showed lower rates of de novo anti-HLA DSA (P = .001) and clinical AMR (P = .018) than ABOc KTRs. Among 25 ABOi protocol biopsies analyzed with MMDx, 56% met AMR criteria due to anti-A/B DSA: 20% active AMR, 20% probable AMR and 16% chronic AMR. However, molecular AMR was confirmed in only 14% by MMDx (P < .001). ABOi and DSA-negative, C4d-negative ABOc biopsies with an MVI below threshold did not differ in molecular rejection, archetype and lesion scores (P > .05) and showed stable graft function. Molecular AMR classifier scores were significantly lower in ABOi and DSA-negative, C4d-negative ABOc cases with MVI below threshold compared with C4d-positive ABOc and ABOc cases with probable AMR (P = .007). Notably, C4d drives molecular AMR activity in ABOc biopsies already at C4d1 levels by immunofluorescence (P = .011) and even in the absence of a histological Banff AMR diagnosis (P = .003).
conclusionABOi transplantation reduces the risk of developing de novo anti-HLA DSA. Banff 2022 criteria may over-diagnose AMR. Biopsy-based transcript diagnostics differentiate anti-HLA- and anti-A/B-mediated alloimmune injury from C4d deposition due to accommodation. Interestingly, C4d deposition drives molecular AMR activity in ABOc biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.